Mettings and Courses

Mettings and Courses

Announcements for this section should be submitted in the correct format at least 3 months before the required date of publication. This list is provided as a service to readers; inclusion does not imply endorsement by the Hepatobiliary & Pancreatic Diseases International.

Section editor

Shui-Ying Lei

Email: hbpdint@126.com

December, 2016

ESMO Asia 2016 congress

December 16-19, 2016; Singapore

The ESMO Asia 2016 congress will take place in Singapore on December 16-19, 2016. This congress will comprise both scientific and educational tracks prepared by an international scientific committee, all experts in their respective fields. The program will have a strong emphasis on state of the art science, including a call for abstracts, and cover the current standard of care across all major tumor types. Interactive sessions will be dedicated to the latest ESMO Clinical Practice Guidelines and there will be opportunities for delegates to interact both with local experts and key opinion leaders from the international oncology community. ESMO Asia facilitates information exchange between Asian and European oncology professionals and offers a global benefit—the exchange of expertise across continents. For further information, please visit: http://www.esmo.org/Conferences/ESMO-Asia-2016-Congress/About-the-Meeting/ Welcome-from-the-Congress-Officers.

January, 2017

Precision medicine series: opportunities and challenges of exploiting synthetic lethality in cancer

January 4-7, 2017; Hard Rock Hotel, San Diego, California, USA

The focus of this AACR special conference is to bring together basic, translational, and clinical scientists working on exploiting these co-dependencies in cancer. The concept of synthetic lethality is derived from classical genetics and has been widely explored in model organisms. Recent advances in technology now permit similar types of studies to be performed in mammalian cells. The recent approval of the use of PARP inhibitors for the treatment of ovarian cancer patients that harbor BRCA1 mutations provides proof-of-principle evidence that targeting such co-dependencies represents a viable therapeutic strategy. This conference will include presentations representing the full spectrum of research, from model organisms to clinical studies, to cover all aspects of this rapidly developing field. For further information, please visit: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=97#.WCLeG-wQgfk.

AACR international conference on new frontiers in cancer research

January 18-22, 2017; The Westin Cape Town, Cape Town, South Africa

This innovative program will bring the forefront of cancer science to Africa and will appeal to a broad spectrum of cancer researchers—from laboratory scientists to physicians in all disciplines of the cancer field. As part of AACR’s international efforts; the meeting will feature talks from leading basic, translational, and clinical researchers across the hottest areas in cancer research. The program will also feature several sessions dedicated to cancers that have a high rate of incidence in Africa and supplement international speakers with experts throughout the region. In addition to the disease sites of particular interest to local researchers and clinicians, the program will feature sessions on DNA repair, epigenetics, genomic medicine, immunotherapy, molecular targets, prevention, and viruses and cancer. For further information, please visit: http://www.aacr.org/Meetings/ Pages/MeetingDetail.aspx?EventItemID=103#.WCLfIO-wQgfk.

February

RNA therapeutics 2017

February 22-23, 2017; London, UK

SMi’s 8th annual RNA therapeutics conference will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems. This exciting program for 2017 will showcase new developments through clinical and pre-clinical results in topics such as: messenger RNA-based therapeutics, anti-sense oligonucleotides and new sites for RNA silencing. Attendees are to: 1) Discover the exciting developments of mRNA and antisense oligonucleotide based therapeutics; 2) Find out how pharmaceutical and biotech companies are strategically improving drug delivery systems; 3) Discuss clinical developments and take away key lessons for future developments; 4) Understand the pharmacokinetic considerations of oligonucleotides and RNA therapies; and

5) Hear how the experts navigate the regulatory landscape. For further details and to register, please visit: http://www.therapeutics-rna.com/gelseiver.

3D cell culture

February 22-23, 2017; London, UK

3D cell culture 2017 will bring together leading professionals and researchers in the industry to discuss the latest developments and future potential of this technique. 3D cell culture 2017 will present success stories 3D culture applications, identifying the newest and brightest technologies, and the translation of 3D models into successful clinical and industrial applications. There will be emphasis on the success and future of 3D methods in organoid research, disease modeling and toxicology screening, stem cell research, and much more. Attendees include Directors, Supervisors, Specialists, Principal Scientists, Product Managers, Science Officer, Chief Scientific Officer, CEO, COO, Project Manager, Lead Scientists, Senior Scientists, Project leaders, Labheads, Research Scientists, Engineers, Senior Pharmacologists, and Professors in the following areas: Cell culture; Stem cell and regenerative medicine; Process development -early and late stage; Large scale manufacturing; Cell therapy; Cell technology; High Throughput Screening; Assay development and screening; and Business development. For further information, please visit: http://www.smi-online.co.uk/pharmaceuticals/uk/3DCell-Culture?utm_medium=www.3d-cellculture. com&utm_source=P-220&utm_campaign=glob.

2nd exploring DNA repair pathways as targets for cancer therapy conference

February 27-March 2, 2017; Cancun, Mexico

The purpose of this conference is to bring together basic, translational and clinical investigators and discuss the current and future directions, opportunities and obstacles in the development of these anti-cancer modalities and how to best apply these concepts in clinical practice. Key sessions include: 1) Highlight recent advances in the field of DNA damage repair; 2) Identify novel targets in DNA repair and checkpoint pathways; 3) Explore the concept of synthetic lethality for cancer treatment; 4) Assess the therapeutic potential of new anti-cancer modalities; and 5) Learn mechanisms of therapeutic resistance and ways to improve cancer therapy. For further information, please visit: https://www.fusion-conferences.com/conference46.php.

April

AACR annual meeting 2017

April 1-5, 2017; Walter E. Washington Convention Center, Washington, D.C., USA

The AACR annual meeting highlights the best cancer science and medicine from institutions all over the world. Program committee chair is Professor Kornelia Polyak from Dana-Farber Cancer Institute, Boston, Massachusetts. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research. Continuing Medical Education Activity AMA PRA Category 1 Credits? is available. For further information, please visit: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&utm_source=aacrorg&utm_campaign=am17&utm_medium=mouseover.

May

2017 joint international congress of ILTS, ELITA & LICAGE

May 24-27, 2017; Prague Congress Center, Czech Republic

The 2017 joint international congress of ILTS, ELITA & LICAGE will be held on May 24-27, 2017 at the Prague Congress Centre. Over 1200 professionals from over 40 countries who are dedicated to promoting and learning about the scientific advances in liver transplantation are brought together to discuss the latest advances in liver transplantation procedures and therapy. The goal of this congress is to broaden the education of scientists, surgeons, anesthesiologists, physicians, nurses, and organ procurement personnel in the care and treatment of liver transplant patients. For further information, please contact: ILTS 2017 Registration Department, Allison Jansen, Tel: +49-30-24603-410; Email: ilts2017registration@kitgroup.org; website: http://2017.ilts.org/.

10.1016/S1499-3872(16)60161-3)